{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:44:19Z","timestamp":1793835859173,"version":"4.6.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s15010-022-01842-7","type":"journal-article","created":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T10:03:49Z","timestamp":1653041029000},"page":"859-871","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["The impact of antibiotics on clinical response over time in uncomplicated cellulitis: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1547-4634","authenticated-orcid":false,"given":"Krishan","family":"Yadav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Krzyzaniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Alexander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Mae","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Glasziou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerben","family":"Keijzers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,20]]},"reference":[{"key":"1842_CR1","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1001\/jama.2016.8825","volume":"316","author":"AB Raff","year":"2016","unstructured":"Raff AB, Kroshinsky D. Cellulitis: a review. JAMA. 2016;316:325\u201337.","journal-title":"JAMA"},{"key":"1842_CR2","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.annemergmed.2007.12.004","volume":"51","author":"DJ Pallin","year":"2008","unstructured":"Pallin DJ, Egan DJ, Pelletier AJ, et al. Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus. Ann Emerg Med. 2008;51:291\u20138.","journal-title":"Ann Emerg Med"},{"key":"1842_CR3","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1017\/S1481803500011623","volume":"11","author":"R Stenstrom","year":"2009","unstructured":"Stenstrom R, Grafstein E, Romney M, et al. Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus skin and soft tissue infection in a Canadian emergency department. CJEM. 2009;11:430\u20138.","journal-title":"CJEM"},{"key":"1842_CR4","unstructured":"Australian Commission on Safety and Quality in Health Care and Australian Institute of Health and Welfare. The Fourth Australian Atlas of Healthcare Variation. Sydney: ACSQHC; 2021. https:\/\/www.safetyandquality.gov.au\/sites\/default\/files\/2021-04\/The%20Fourth%20Australian%20Atlas%20of%20Healthcare%20Variation%202021_Full%20publication.pdf. Published 2021."},{"key":"1842_CR5","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004299.pub2","author":"SA Kilburn","year":"2010","unstructured":"Kilburn SA, Featherstone P, Higgins B, et al. Interventions for cellulitis and erysipelas. Cochrane Database Syst Rev. 2010. https:\/\/doi.org\/10.1002\/14651858.CD004299.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"1842_CR6","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1093\/jac\/dku397","volume":"70","author":"CA Aboltins","year":"2015","unstructured":"Aboltins CA, Hutchinson AF, Sinnappu RN, et al. Oral versus parenteral antimicrobials for the treatment of cellulitis: a randomized non-inferiority trial. J Antimicrob Chemother. 2015;70:581\u20136.","journal-title":"J Antimicrob Chemother"},{"key":"1842_CR7","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1136\/bmj.325.7369.864","volume":"325","author":"P Bernard","year":"2002","unstructured":"Bernard P, Chosidow O, Vaillant L. Oral pristinamycin versus standard penicillin regimen to treat erysipelas in adults: randomised, non-inferiority, open trial. BMJ. 2002;325:864.","journal-title":"BMJ"},{"key":"1842_CR8","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1093\/cid\/ciu296","volume":"59","author":"DL Stevens","year":"2014","unstructured":"Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59:e10-52.","journal-title":"Clin Infect Dis"},{"key":"1842_CR9","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1017\/cem.2016.347","volume":"19","author":"K Yadav","year":"2017","unstructured":"Yadav K, Gatien M, Corrales-Medina V, et al. Antimicrobial treatment decision for non-purulent skin and soft tissue infections in the emergency department. CJEM. 2017;19:175\u201380.","journal-title":"CJEM"},{"key":"1842_CR10","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/1742-6723.13383","volume":"31","author":"LM Hamill","year":"2019","unstructured":"Hamill LM, Thi YE, Keijzers G. Picking the low-hanging fruit: why not choose oral antibiotics for skin and soft-tissue infections in the emergency department. Emerg Med Australas. 2019;31:1119\u201322.","journal-title":"Emerg Med Australas"},{"key":"1842_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s15010-019-01347-w","volume":"48","author":"K Yadav","year":"2020","unstructured":"Yadav K, Nath A, Suh KN, et al. Treatment failure definitions for non-purulent skin and soft tissue infections: a systematic review. Infection. 2020;48:75\u201383.","journal-title":"Infection"},{"key":"1842_CR12","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1001\/jama.2017.5653","volume":"317","author":"GJ Moran","year":"2017","unstructured":"Moran GJ, Krishnadasan A, Mower WR, et al. Effect of cephalexin plus trimethoprim-sulfamethoxazole vs cephalexin alone on clinical cure of uncomplicated cellulitis: a randomized clinical trial. JAMA. 2017;317:2088\u201396.","journal-title":"JAMA"},{"key":"1842_CR13","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.jinf.2020.07.030","volume":"81","author":"ELA Cross","year":"2020","unstructured":"Cross ELA, Jordan H, Godfrey R, et al. Route and duration of antibiotic therapy in acute cellulitis: a systematic review and meta-analysis of the effectiveness and harms of antibiotic treatment. J Infect. 2020;81:521\u201331.","journal-title":"J Infect"},{"key":"1842_CR14","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/bjd.15634","volume":"177","author":"KS Thomas","year":"2017","unstructured":"Thomas KS, Brindle R, Chalmers JR, et al. Identifying priority areas for research into the diagnosis, treatment and prevention of cellulitis (erysipelas): results of a James Lind Alliance Priority Setting Partnership. Br J Dermatol. 2017;177:541\u20133.","journal-title":"Br J Dermatol"},{"key":"1842_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339: b2535.","journal-title":"BMJ"},{"key":"1842_CR16","doi-asserted-by":"publisher","first-page":"195","DOI":"10.5195\/jmla.2020.834","volume":"108","author":"JM Clark","year":"2020","unstructured":"Clark JM, Sanders S, Carter M, et al. Improving the translation of search strategies using the Polyglot Search Translator: a randomized controlled trial. J Med Libr Assoc. 2020;108:195\u2013207.","journal-title":"J Med Libr Assoc"},{"key":"1842_CR17","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/jrsm.1287","volume":"9","author":"IJ Marshall","year":"2018","unstructured":"Marshall IJ, Noel-Storr A, Kuiper J, et al. Machine learning for identifying Randomized Controlled Trials: an evaluation and practitioner\u2019s guide. Res Synth Methods. 2018;9:602\u201314.","journal-title":"Res Synth Methods"},{"key":"1842_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604","volume-title":"Cochrane handbook for systematic review of interventions","author":"J Higgins","year":"2019","unstructured":"Higgins J, Thomas J, Chandler J, et al. Cochrane handbook for systematic review of interventions. 2nd ed. Chichester: Wiley; 2019.","edition":"2"},{"key":"1842_CR19","unstructured":"Graph twoway qfit - Twoway quadratic prediction plots. https:\/\/www.stata.com\/manuals\/g-2graphtwowayqfit.pdf."},{"key":"1842_CR20","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/S0149-2918(02)80024-8","volume":"24","author":"AD Bucko","year":"2002","unstructured":"Bucko AD, Hunt BJ, Kidd SL, et al. Randomized, double-blind, multicenter comparison of oral cefditoren 200 or 400 mg BID with either cefuroxime 250 mg BID or cefadroxil 500 mg BID for the treatment of uncomplicated skin and skin-structure infections. Clin Ther. 2002;24:1134\u201347.","journal-title":"Clin Ther"},{"key":"1842_CR21","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1001\/archinte.164.15.1669","volume":"164","author":"MJ Hepburn","year":"2004","unstructured":"Hepburn MJ, Dooley DP, Skidmore PJ, et al. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med. 2004;164:1669\u201374.","journal-title":"Arch Intern Med"},{"key":"1842_CR22","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1093\/cid\/cix987","volume":"66","author":"DB Huang","year":"2018","unstructured":"Huang DB, O\u2019Riordan W, Overcash JS, et al. A phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of intravenous iclaprim vs vancomycin for the treatment of acute bacterial skin and skin structure infections suspected or confirmed to be due to gram-positive pathogens: REVIVE-1. Clin Infect Dis. 2018;66:1222\u20139.","journal-title":"Clin Infect Dis"},{"key":"1842_CR23","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1093\/jac\/dkv411","volume":"71","author":"J Kingsley","year":"2016","unstructured":"Kingsley J, Mehra P, Lawrence LE, et al. A randomized, double-blind, Phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin. J Antimicrob Chemother. 2016;71:821\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"1842_CR24","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/j.1365-4362.1992.tb02683.x","volume":"31","author":"BA Lipsky","year":"1992","unstructured":"Lipsky BA, Yarbrough DR 3rd, Walker FBT, et al. Ofloxacin versus cephalexin for treating skin and soft tissue infections. Int J Dermatol. 1992;31:443\u20135.","journal-title":"Int J Dermatol"},{"key":"1842_CR25","doi-asserted-by":"publisher","first-page":"ofw274","DOI":"10.1093\/ofid\/ofw274","volume":"4","author":"TP Lodise","year":"2017","unstructured":"Lodise TP, Redell M, Armstrong SO, et al. Efficacy and safety of oritavancin relative to vancomycin for patients with acute bacterial skin and skin structure infections (ABSSSI) in the outpatient setting: results from the SOLO clinical trials. Open Forum Infect Dis. 2017;4:ofw274.","journal-title":"Open Forum Infect Dis"},{"key":"1842_CR26","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S1473-3099(19)30275-0","volume":"19","author":"W O'Riordan","year":"2019","unstructured":"O\u2019Riordan W, Cardenas C, Shin E, et al. Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial. Lancet Infect Dis. 2019;19:1080\u201390.","journal-title":"Lancet Infect Dis"},{"key":"1842_CR27","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/cid\/cit122","volume":"56","author":"DJ Pallin","year":"2013","unstructured":"Pallin DJ, Binder WD, Allen MB, et al. Clinical trial: comparative effectiveness of cephalexin plus trimethoprim-sulfamethoxazole versus cephalexin alone for treatment of uncomplicated cellulitis: a randomized controlled trial. Clin Infect Dis. 2013;56:1754\u201362.","journal-title":"Clin Infect Dis"},{"key":"1842_CR28","doi-asserted-by":"publisher","first-page":"3471","DOI":"10.1093\/jac\/dkx329","volume":"72","author":"J Pullman","year":"2017","unstructured":"Pullman J, Gardovskis J, Farley B, et al. Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a phase 3, double-blind, randomized study. J Antimicrob Chemother. 2017;72:3471\u201380.","journal-title":"J Antimicrob Chemother"},{"key":"1842_CR29","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/S0149-2918(98)80088-X","volume":"20","author":"KJ Tack","year":"1998","unstructured":"Tack KJ, Littlejohn TW, Mailloux G, et al. Cefdinir versus cephalexin for the treatment of skin and skin-structure infections. The Cefdinir Adult Skin Infection Study Group. Clin Ther. 1998;20:244\u201356.","journal-title":"Clin Ther"},{"key":"1842_CR30","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1128\/AAC.45.8.2358-2362.2001","volume":"45","author":"GA Tarshis","year":"2001","unstructured":"Tarshis GA, Miskin BM, Jones TM, et al. Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study. Antimicrob Agents Chemother. 2001;45:2358\u201362.","journal-title":"Antimicrob Agents Chemother"},{"key":"1842_CR31","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00250-20","author":"F Wittke","year":"2020","unstructured":"Wittke F, Vincent C, Chen J, et al. Afabicin, a first-in-class antistaphylococcal antibiotic, in the treatment of acute bacterial skin and skin structure infections: clinical noninferiority to vancomycin\/linezolid. Antimicrob Agents Chemother. 2020. https:\/\/doi.org\/10.1128\/AAC.00250-20.","journal-title":"Antimicrob Agents Chemother"},{"key":"1842_CR32","doi-asserted-by":"publisher","first-page":"ofz335","DOI":"10.1093\/ofid\/ofz335","volume":"6","author":"MC Clarke","year":"2019","unstructured":"Clarke MC, Cheng AC, Pollard JG, et al. Lessons learned from a randomized controlled trial of short-course intravenous antibiotic therapy for erysipelas and cellulitis of the lower limb (switch trial). Open Forum Infect Dis. 2019;6:ofz335.","journal-title":"Open Forum Infect Dis"},{"key":"1842_CR33","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.cmi.2017.02.036","volume":"23","author":"JS Davis","year":"2017","unstructured":"Davis JS, Mackrow C, Binks P, et al. A double-blind randomized controlled trial of ibuprofen compared to placebo for uncomplicated cellulitis of the upper or lower limb. Clin Microbiol Infect. 2017;23:242\u20136.","journal-title":"Clin Microbiol Infect"},{"key":"1842_CR34","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S1473-3099(18)30729-1","volume":"19","author":"LF Ibrahim","year":"2019","unstructured":"Ibrahim LF, Hopper SM, Orsini F, et al. Efficacy and safety of intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis (CHOICE): a single-centre, open-label, randomised, controlled, non-inferiority trial. Lancet Infect Dis. 2019;19:477\u201386.","journal-title":"Lancet Infect Dis"},{"key":"1842_CR35","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1136\/emj.2004.019869","volume":"22","author":"P Leman","year":"2005","unstructured":"Leman P, Mukherjee D. Flucloxacillin alone or combined with benzylpenicillin to treat lower limb cellulitis: a randomised controlled trial. Emerg Med J. 2005;22:342\u20136.","journal-title":"Emerg Med J"},{"key":"1842_CR36","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1365-2133.1992.tb08048.x","volume":"127","author":"P Bernard","year":"1992","unstructured":"Bernard P, Plantin P, Roger H, et al. Roxithromycin versus penicillin in the treatment of erysipelas in adults: a comparative study. Br J Dermatol. 1992;127:155\u20139.","journal-title":"Br J Dermatol"},{"key":"1842_CR37","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.cmi.2019.09.019","volume":"26","author":"DR Cranendonk","year":"2020","unstructured":"Cranendonk DR, Opmeer BC, van Agtmael MA, et al. Antibiotic treatment for 6 days versus 12 days in patients with severe cellulitis: a multicentre randomized, double-blind, placebo-controlled, non-inferiority trial. Clin Microbiol Infect. 2020;26:606\u201312.","journal-title":"Clin Microbiol Infect"},{"key":"1842_CR38","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1136\/bmj.38309.447975.EB","volume":"330","author":"P Corwin","year":"2005","unstructured":"Corwin P, Toop L, McGeoch G, et al. Randomised controlled trial of intravenous antibiotic treatment for cellulitis at home compared with hospital. BMJ. 2005;330:129.","journal-title":"BMJ"},{"key":"1842_CR39","doi-asserted-by":"publisher","first-page":"377","DOI":"10.3109\/00365549709011834","volume":"29","author":"PI Bergkvist","year":"1997","unstructured":"Bergkvist PI, Sj\u00f6beck K. Antibiotic and prednisolone therapy of erysipelas: a randomized, double blind, placebo-controlled study. Scand J Infect Dis. 1997;29:377\u201382.","journal-title":"Scand J Infect Dis"},{"key":"1842_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013260","volume":"7","author":"R Brindle","year":"2017","unstructured":"Brindle R, Williams OM, Davies P, et al. Adjunctive clindamycin for cellulitis: a clinical trial comparing flucloxacillin with or without clindamycin for the treatment of limb cellulitis. BMJ Open. 2017;7: e013260.","journal-title":"BMJ Open"},{"key":"1842_CR41","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","volume":"370","author":"HW Boucher","year":"2014","unstructured":"Boucher HW, Wilcox M, Talbot GH, et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370:2169\u201379.","journal-title":"N Engl J Med"},{"key":"1842_CR42","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02252-18","author":"X Lv","year":"2019","unstructured":"Lv X, Alder J, Li L, et al. Efficacy and safety of tedizolid phosphate versus linezolid in a randomized phase 3 trial in patients with acute bacterial skin and skin structure infection. Antimicrob Agents Chemother. 2019. https:\/\/doi.org\/10.1128\/AAC.02252-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"1842_CR43","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1093\/jac\/37.suppl_C.125","volume":"37","author":"L Montero","year":"1996","unstructured":"Montero L. A comparative study of the efficacy, safety and tolerability of azithromycin and cefaclor in the treatment of children with acute skin and\/or soft tissue infections. J Antimicrob Chemother. 1996;37:125\u201331.","journal-title":"J Antimicrob Chemother"},{"key":"1842_CR44","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/S1473-3099(14)70737-6","volume":"14","author":"GJ Moran","year":"2014","unstructured":"Moran GJ, Fang E, Corey GR, et al. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2014;14:696\u2013705.","journal-title":"Lancet Infect Dis"},{"key":"1842_CR45","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1056\/NEJMoa1800170","volume":"380","author":"W O'Riordan","year":"2019","unstructured":"O\u2019Riordan W, Green S, Overcash JS, et al. Omadacycline for acute bacterial skin and skin-structure infections. N Engl J Med. 2019;380:528\u201338.","journal-title":"N Engl J Med"},{"key":"1842_CR46","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/j.1742-1241.2008.01988.x","volume":"63","author":"PE Pertel","year":"2009","unstructured":"Pertel PE, Eisenstein BI, Link AS, et al. The efficacy and safety of daptomycin vs vancomycin for the treatment of cellulitis and erysipelas. Int J Clin Pract. 2009;63:368\u201375.","journal-title":"Int J Clin Pract"},{"key":"1842_CR47","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1001\/jama.2013.241","volume":"309","author":"P Prokocimer","year":"2013","unstructured":"Prokocimer P, De Anda C, Fang E, et al. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA. 2013;309:559\u201369.","journal-title":"JAMA"},{"key":"1842_CR48","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1093\/jac\/31.suppl_E.103","volume":"31","author":"A Rodriguez-Solares","year":"1993","unstructured":"Rodriguez-Solares A, P\u00e9rez-Guti\u00e9rrez F, Prosperi J, et al. A comparative study of the efficacy, safety and tolerance of azithromycin, dicloxacillin and flucloxacillin in the treatment of children with acute skin and skin-structure infections. J Antimicrob Chemother. 1993;31:103\u20139.","journal-title":"J Antimicrob Chemother"},{"key":"1842_CR49","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1001\/jamadermatol.2019.0884","volume":"155","author":"R Brindle","year":"2019","unstructured":"Brindle R, Williams OM, Barton E, et al. Assessment of antibiotic treatment of cellulitis and erysipelas: a systematic review and meta-analysis. JAMA Dermatol. 2019;155:1033\u201340.","journal-title":"JAMA Dermatol"},{"key":"1842_CR50","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1093\/cid\/ciw463","volume":"63","author":"T Bruun","year":"2016","unstructured":"Bruun T, Oppegaard O, Hufthammer KO, et al. Early response in cellulitis: a prospective study of dynamics and predictors. Clin Infect Dis. 2016;63:1034\u201341.","journal-title":"Clin Infect Dis"},{"key":"1842_CR51","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1093\/cid\/cis566","volume":"55","author":"GH Talbot","year":"2012","unstructured":"Talbot GH, Powers JH, Fleming TR, et al. Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health. Clin Infect Dis. 2012;55:1114\u201321.","journal-title":"Clin Infect Dis"},{"key":"1842_CR52","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s13063-017-1978-4","volume":"18","author":"PR Williamson","year":"2017","unstructured":"Williamson PR, Altman DG, Bagley H, et al. The COMET handbook: version 1.0. Trials. 2017;18:280.","journal-title":"Trials"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-022-01842-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-022-01842-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-022-01842-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T10:21:12Z","timestamp":1659090072000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-022-01842-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,20]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["1842"],"URL":"https:\/\/doi.org\/10.1007\/s15010-022-01842-7","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,20]]},"assertion":[{"value":"24 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}